Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Aim: Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. The aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Methods: Data on 153 patients were reviewed. The study population was classified into three groups: 73 (47.8%) patients who received neither angiotensin‐converting enzyme inhibitors nor sartans (group 1), 49 (32%) patients treated with angiotensin‐converting enzyme inhibitors (group 2), and 31 (20.2%) patients treated with sartans (group 3). Survival outcomes were analysed by means of K aplan–M eier analysis and compared with log–rank test. Results: In the whole study population, 85.6% of patients were in C hild–P ugh A class and 89.6% in B arcelona C linic L iver C ancer A stage. Median maximum tumor diameter was 30 mm (10–40) and alpha fetoprotein was 25 (1.1–2100) UI/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (95% confidence interval: 31–58) in group 1, 72 months (49–89) in group 2, and 84 months (58–92) in group 3 (P = 0.02). Median time to recurrence was 26 (15–42), 44 (33–72), and 69 (44–74) months in the three groups, respectively (P = 0.02). Sartan therapy was a significant predictor of longer overall survival and delayed time to recurrence on multivariate analysis. Conclusion: Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Mazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006) · Hepatology · doi:10.1002/hep.21415 · Cited by 367
Cited by
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Zhang, X., Wong, G. L., Yip, T. C., Tse, Y., Liang, L. Y., Hui, V. W., Lin, H., Li, G., Lai, J. C., Chan, H. L., et al. (2022) · Hepatology · doi:10.1002/hep.32294 · Cited by 93
Levin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2528-3 · Cited by 51
“Several retrospective clinical studies in non-CNS cancers have shown improved survival with ASIs, including but not limited to NSCLC, renal cell carcinoma, and hepatocellular carcinoma [13, 20, 21].”
Background
Metadata
- Authors
- Facciorusso, A., Del Prete, V., Crucinio, N., Muscatiello, N., Carr, B. I., Di Leo, A., & Barone, M.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2015-10-12
- Volume
- 30
- Issue
- 11
- Pages
- 1643-1650
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2156901310
- Cited by
- 75
- References
- 3
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. https://app.cochat.ai/papers/10.1111/jgh.12988
- The paper
- Facciorusso, A., Del Prete, V., Crucinio, N., Muscatiello, N., Carr, B. I., Di Leo, A., & Barone, M. (2015). Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.12988
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.